MCM
VRTX icon

Mengis Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mengis Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Hold
500
– – 0.04% 203
2025
Q4 		$227K Buy
+500
New +$216K 0.04% 199
2025
Q3 		– Sell
-500
Closed -$223K – 211
2025
Q2 		$223K Buy
+500
New +$230K 0.05% 186

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mengis Capital Management's VRTX Position: Q1 2026 in Review

Mengis Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 500 shares worth $223K. The position accounts for 0.04% of the portfolio, ranked #203.

Mengis Capital Management first reported a position in VRTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $227K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Mengis Capital Management held 500 shares of Vertex Pharmaceuticals worth $223K as of Q1 2026.
  • Mengis Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.04% of Mengis Capital Management's portfolio in Q1 2026, its #203 holding.
  • Mengis Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Mengis Capital Management's Vertex Pharmaceuticals position peaked at $227K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.